VANCOUVER, BC, Nov. 10, 2023 /CNW/ - CareSpan Health, Inc. (TSXV: CSPN) ("Company" or "CareSpan"), is pleased to announce the results of the Company's annual general and special meeting (the "Meeting") held virtually on November 8, 2023.
Votes For | |
Fix the number of directors to be elected at four (4). | 99.56 % |
Election of directors | |
(i) Rembert de Villa | 94.09 % |
(ii) Holger Micheel Sprenger | 99.56 % |
(iii) Sam Toney | 94.09 % |
(iv) Poonacha Machaiah | 99.56 % |
Re-appointment of MNP LLP, Chartered Professional Accountants as the Company's auditors. | 99.56 % |
*Approval of prior grants under the Company's existing stock option plan. | 79.24 % |
*Approval of the Company's new equity incentive plan. | 79.24 % |
*Approval was sought from disinterested shareholders of the Company. |
A total of 22,862,093 common shares of the Company (the "Common Shares") were present in person or by proxy at the Meeting, which constituted a quorum of shareholders, and represented 48.35% of the 47,282,297 issued and outstanding Common Shares entitled to vote as of October 3, 2023, the record date of the Meeting.
For more information on the matters approved by shareholders at the Meeting, please refer to the Company's management information circular dated October 4, 2023, that is available on SEDAR+ (www.sedarplus.com).
About CareSpan Health, Inc.
CareSpan is a healthcare technology and services company that has developed and deployed a unique, proprietary integrated digital care platform, the CareSpan Clinic-in-the Cloud™, that creates easy access to care for the underserved. With a patient-centric approach focused on improving health outcomes, CareSpan uses sophisticated digital tools and capabilities to improve patient outcomes in primary care, chronic care, urgent care, and mental health. In addition to the integrated digital care platform, CareSpan has built and deployed a business support infrastructure for its professional networks, American-Advanced Practice Network and AmericanMedPsych Network. American-Advanced Practice Network harnesses the clinical capabilities of Nurse Practitioners to address the shortage in primary and chronic care in the country. AmericanMedPsych brings together providers to tackle shortages mainly in mental health.
Clinic-in-the-Cloud is a trademark of CareSpan USA Inc., a subsidiary of CareSpan Health, Inc.
ON BEHALF OF THE BOARD OF DIRECTORS:
Rembert de Villa
Director and Chief Executive Officer
For more information, visit: www.carespanhealth.com
Forward-Looking Statements Disclaimer and Reader Advisory
This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, "subject to", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be achieved. These forward-looking statements are based on assumptions. The actual results may be materially different from any future expectations expressed or implied by the forward-looking statements. The forward-looking statements can be affected by known and unknown risks, uncertainties and other factors.
Except as required by law, CareSpan undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Trading in the securities of the Company should be considered highly speculative.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Last Trade: | C$0.02 |
Daily Volume: | 0 |
Market Cap: | C$952K |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load